|
1
|
Mangiameli G, Cioffi U, Alloisio M and
Testori A: Lung metastases: Current surgical indications and new
perspectives. Front Surg. 9:8849152022. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
J Saller J and Boyle TA: Molecular
pathology of lung cancer. Cold Spring Harb Perspect Med.
12:a0378122022. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Isaacs J and Stinchcombe TE: Neoadjuvant
and adjuvant systemic therapy for early-stage non-small-cell lung
cancer. Drugs. 82:855–863. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tabbò F, DE Filippis M, Jacobs F and
Novello S: Strengths and pitfalls of brigatinib in non-small cell
lung cancer patients' management. Minerva Med. 113:315–332. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Thomas AF, Kelly GL and Strasser A: Of the
many cellular responses activated by TP53, which ones are critical
for tumour suppression? Cell Death Differ. 29:961–971. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Koo N, Sharma AK and Narayan S:
Therapeutics targeting p53-MDM2 interaction to induce cancer cell
death. Int J Mol Sci. 23:50052022. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang S and Chen FE: Small-molecule MDM2
inhibitors in clinical trials for cancer therapy. Eur J Med Chem.
236:1143342022. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jiang H, Luo J and Lei H: The roles of
mouse double minute 2 (MDM2) oncoprotein in ocular diseases: A
review. Exp Eye Res. 217:1089102022. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chène P: Inhibiting the p53-MDM2
interaction: An important target for cancer therapy. Nat Rev
Cancer. 3:102–109. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jeong MH, Yang K, Lee CG, Jeong DH, Park
YS, Choi YJ, Kim JS, Oh SJ, Jeong SK and Jo WS: In vitro
genotoxicity assessment of a novel resveratrol analogue, HS-1793.
Toxicol Res. 30:211–220. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Saiko P, Szakmary A, Jaeger W and Szekeres
T: Resveratrol and its analogs: Defense against cancer, coronary
disease and neurodegenerative maladies or just a fad? Mutat Res.
658:68–94. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jeong SH, Jo WS, Song S, Suh H, Seol SY,
Leem SH, Kwon TK and Yoo YH: A novel resveratrol derivative,
HS1793, overcomes the resistance conferred by Bcl-2 in human
leukemic U937 cells. Biochem Pharmacol. 77:1337–1347. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jeong SH, Lee JS, Jeong NY, Kim TH, Yoo
KS, Song S, Suh H, Kwon TK, Park BS and Yoo YH: A novel resveratrol
analogue HS-1793 treatment overcomes the resistance conferred by
Bcl-2 and is associated with the formation of mature PML nuclear
bodies in renal clear cell carcinoma Caki-1 cells. Int J Oncol.
35:1353–1360. 2009.PubMed/NCBI
|
|
14
|
Jeong SH, Song IS, Kim HK, Lee SR, Song S,
Suh H, Yoon YG, Yoo YH, Kim N, Rhee BD, et al: An analogue of
resveratrol HS-1793 exhibits anticancer activity against MCF-7
cells via inhibition of mitochondrial biogenesis gene expression.
Mol Cells. 34:357–365. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jeong NY, Yoon YG, Rho JH, Lee JS, Lee SY,
Yoo KS, Song S, Suh H, Choi YH and Yoo YH: The novel resveratrol
analog HS-1793-induced polyploid LNCaP prostate cancer cells are
vulnerable to downregulation of Bcl-xL. Int J Oncol. 38:1597–1604.
2011.PubMed/NCBI
|
|
16
|
Kim DH, Kim MJ, Sung B, Suh H, Jung JH,
Chung HY and Kim ND: Resveratrol analogue, HS-1793, induces
apoptotic cell death and cell cycle arrest through downregulation
of AKT in human colon cancer cells. Oncol Rep. 37:281–288. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Song IS, Jeong YJ, Jeong SH, Kim HK, Ha
NC, Shin M, Ko KS, Rhee BD, Shim S, Jang SW and Han J:
Pharmacologic inhibition of AKT leads to cell death in relapsed
multiple myeloma. Cancer Lett. 432:205–215. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kim JA, Kim DH, Hossain MA, Kim MY, Sung
B, Yoon JH, Suh H, Jeong TC, Chung HY and Kim ND: HS-1793, a
resveratrol analogue, induces cell cycle arrest and apoptotic cell
death in human breast cancer cells. Int J Oncol. 44:473–480. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kim DH, Hossain MA, Kim MY, Kim JA, Yoon
JH, Suh HS, Kim GY, Choi YH, Chung HY and Kim ND: A novel
resveratrol analogue, HS-1793, inhibits hypoxia-induced HIF-1α and
VEGF expression, and migration in human prostate cancer cells. Int
J Oncol. 43:1915–1924. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Minna JD, Roth JA and Gazdar AF: Focus on
lung cancer. Cancer Cell. 1:49–52. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lemjabbar-Alaoui H, Hassan OU, Yang YW and
Buchanan P: Lung cancer: Biology and treatment options. Biochim
Biophys Acta. 1856:189–210. 2015.PubMed/NCBI
|
|
22
|
Gridelli C, Rossi A, Carbone DP, Guarize
J, Karachaliou N, Mok T, Petrella F, Spaggiari L and Rosell R:
Non-small-cell lung cancer. Nat Rev Dis Primers. 1:150092015.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zappa C and Mousa SA: Non-small cell lung
cancer: Current treatment and future advances. Transl Lung Cancer
Res. 5:288–300. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hoffman PC, Mauer AM and Vokes EE: Lung
cancer. Lancet. 355:479–485. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Herbst RS, Morgensztern D and Boshoff C:
The biology and management of non-small cell lung cancer. Nature.
553:446–454. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yang K, Wang YJ, Chen XR and Chen HN:
Effectiveness and safety of bevacizumab for unresectable
non-small-cell lung cancer: A meta-analysis. Clin Drug Investig.
30:229–241. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Silk N, Reich J, Sinha R, Chawla S, Geary
K and Zhang D: The effects of resveratrol on prostate cancer
through targeting the tumor microenvironment. J Xenobiot. 11:16–32.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zaffaroni N and Beretta GL: Resveratrol
and prostate cancer: The power of phytochemicals. Curr Med Chem.
28:4845–4862. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Medina-Aguilar R, Marchat LA, Arechaga
Ocampo E, Gariglio P, García Mena J, Villegas Sepúlveda N, Martínez
Castillo M and López-Camarillo C: Resveratrol inhibits cell cycle
progression by targeting Aurora kinase A and Polo-like kinase 1 in
breast cancer cells. Oncol Rep. 35:3696–3704. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Alamolhodaei NS, Tsatsakis AM, Ramezani M,
Hayes AW and Karimi G: Resveratrol as MDR reversion molecule in
breast cancer: An overview. Food Chem Toxicol. 103:223–232. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Schneider Y, Vincent F, Duranton B, Badolo
L, Gossé F, Bergmann C, Seiler N and Raul F: Anti-proliferative
effect of resveratrol, a natural component of grapes and wine, on
human colonic cancer cells. Cancer Lett. 158:85–91. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tessitore L, Davit A, Sarotto I and
Caderni G: Resveratrol depresses the growth of colorectal aberrant
crypt foci by affecting bax and p21(CIP) expression.
Carcinogenesis. 21:1619–1622. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Fabbrocini G, Kisslinger A, Iannelli P,
Vitale N, Procaccini C, Sparaneo G, Chieffi P, Ayala F, Mancini FP
and Tramontano D: Resveratrol regulates p66Shc activation in HaCaT
cells. Exp Dermatol. 19:895–903. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Feng Y, Zhou J and Jiang Y: Resveratrol in
lung cancer-a systematic review. J BUON. 21:950–953.
2016.PubMed/NCBI
|
|
35
|
Rasheduzzaman M, Jeong JK and Park SY:
Resveratrol sensitizes lung cancer cell to TRAIL by p53 independent
and suppression of Akt/NF-κB signaling. Life Sci. 208:208–220.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kong F, Zhang R, Zhao X, Zheng G, Wang Z
and Wang P: Resveratrol raises in vitro anticancer effects of
paclitaxel in NSCLC cell line A549 through COX-2 expression. Korean
J Physiol Pharmacol. 21:465–474. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ohshiro K, Rayala SK, Kondo S, Gaur A,
Vadlamudi RK, El-Naggar AK and Kumar R: Identifying the estrogen
receptor coactivator PELP1 in autophagosomes. Cancer Res.
67:8164–8171. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Luo H, Yang A, Schulte BA, Wargovich MJ
and Wang GY: Resveratrol induces premature senescence in lung
cancer cells via ROS-mediated DNA damage. PLoS One. 8:e600652013.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Whyte L, Huang YY, Torres K and Mehta RG:
Molecular mechanisms of resveratrol action in lung cancer cells
using dual protein and microarray analyses. Cancer Res.
67:12007–12017. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ebi H, Tomida S, Takeuchi T, Arima C, Sato
T, Mitsudomi T, Yatabe Y, Osada H and Takahashi T: Relationship of
deregulated signaling converging onto mTOR with prognosis and
classification of lung adenocarcinoma shown by two independent in
silico analyses. Cancer Res. 69:4027–4035. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Shaito A, Posadino AM, Younes N, Hasan H,
Halabi S, Alhababi D, Al-Mohannadi A, Abdel-Rahman WM, Eid AH,
Nasrallah GK and Pintus G: Potential adverse effects of
resveratrol: A literature review. Int J Mol Sci. 21:20842020.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Neves AR, Lucio M, Lima JL and Reis S:
Resveratrol in medicinal chemistry: A critical review of its
pharmacokinetics, drug-delivery, and membrane interactions. Curr
Med Chem. 19:1663–1681. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kim DH, Hossain MA, Kim MY, Kim JA, Yoon
JH, Suh HS, Kim GY, Choi YH, Chung HY and Kim ND: A novel
resveratrol analogue, HS-1793, inhibits hypoxia-induced HIF-1α and
VEGF expression, and migration in human prostate cancer cells. Int
J Oncol. 43:1915–1924. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Chen Y, Li H, Zhang W, Qi W, Lu C, Huang
H, Yang Z, Liu B and Zhang L: Sesamin suppresses NSCLC cell
proliferation and induces apoptosis via Akt/p53 pathway. Toxicol
Appl Pharmacol. 387:1148482020. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Chibaya L, Karim B, Zhang H and Jones SN:
Mdm2 phosphorylation by Akt regulates the p53 response to oxidative
stress to promote cell proliferation and tumorigenesis. Proc Natl
Acad Sci USA. Jan 26–2021.(Epub aheac of print). View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Zhao Y, Cai J, Shi K, Li H, Du J, Hu D,
Liu Z and Wang W: Germacrone induces lung cancer cell apoptosis and
cell cycle arrest via the Akt/MDM2/p53 signaling pathway. Mol Med
Rep. 23:4522021. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Liu L, Xu Z, Yu B, Tao L and Cao Y:
Berbamine inhibits cell proliferation and migration and induces
cell death of lung cancer cells via regulating c-Maf, PI3K/Akt, and
MDM2-P53 pathways. Evid Based Complement Alternat Med.
2021:55171432021.PubMed/NCBI
|
|
48
|
Aubrey BJ, Kelly GL, Janic A, Herold MJ
and Strasser A: How does p53 induce apoptosis and how does this
relate to p53-mediated tumour suppression? Cell Death Differ.
25:104–113. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Ozaki T and Nakagawara A: Role of p53 in
cell death and human cancers. Cancers (Basel). 3:994–1013. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Shi D and Gu W: Dual roles of MDM2 in the
regulation of p53: Ubiquitination dependent and ubiquitination
independent mechanisms of MDM2 repression of p53 activity. Genes
Cancer. 3:240–248. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Klein AM, de Queiroz RM, Venkatesh D and
Prives C: The roles and regulation of MDM2 and MDMX: It is not just
about p53. Genes Dev. 35:575–601. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Athar M, Elmets CA and Kopelovich L:
Pharmacological activation of p53 in cancer cells. Curr Pharm Des.
17:631–639. 2011. View Article : Google Scholar : PubMed/NCBI
|
